Clinical trials: Diabetes, Type 1
Diabetes, Diabetes Mellitus, Type 1
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics
This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401(insulin degludec/insulin aspart (IDegAsp)) with NN1250 (insulin degludec (IDeg)) and insulin aspart…
- Trial name
- NCT00992537
- Testing
- insulin degludec, insulin degludec/insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Type 1
ACZ885 in Type 1 Diabetes Mellitus
This study will assess the safety and efficacy of ACZ885 on stimulated C-peptide during a mixed meal test in patients with newly-diagnosed type 1 diabetes mellitus.
- Trial name
- NCT01322321
- Testing
- ACZ885
- Where
- 10 sites in United States, Canada and 2 more
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject
- Trial name
- NCT05266404
- Testing
- Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.
- Trial name
- NCT00034255
- Testing
- INGAP Peptide
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- GMP Endotherapeutics
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the absorption and effect in the body of NN1218 in subjects with type 1 and type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01121276
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Novo Nordisk A/S
Type II Diabetes Mellitus
A Clinical Trial to Evaluate the Food Effect of CKD-378
A clinical trial to evaluate the food effect of CKD-378
- Trial name
- NCT06386328
- Testing
- CKD-378, QD, PO
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Type 1 and Type 2 Diabetes Patients Having Switched From Human Premixes to NovoMix®30
This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoMix® 30 for treatment of type 1 and type 2 diabetes under normal clinical practice conditions in…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00675493
- Testing
- biphasic insulin aspart 30
- Where
- Romania
- Volunteers
- 942 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403
This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each.)
- Trial name
- NCT01131091
- Testing
- SK-0403
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Diabetes Mellitus, Type 1
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
INHALE-3 is a Phase 4, randomized controlled trial (RCT) that will randomly assign participants ≥18 years of age with type 1 diabetes (T1D) using multiple daily injections (MDI), an automated insulin delivery (AID) system, or a…
- Trial name
- NCT05904743
- Testing
- Afrezza, insulin degludec, Rapid-acting Insulin Analog
- Where
- 19 sites in United States
- Volunteers
- 141 people
- Sponsor
- Mannkind Corporation
Gastroparesis, Diabetes Mellitus, Type 1
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily…
- Conditions
- Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01452815
- Testing
- 10mg TZP-102, 20mg TZP-102
- Where
- 52 sites in United States, Belgium and 6 more
- Volunteers
- 201 people
- Sponsor
- Tranzyme, Inc.
Diabetes Mellitus, Type 1
Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study
The purpose of this study is to obtain preliminary safety and performance data on planned improvements to Control-IQ technology.
- Trial name
- NCT05014789
- Testing
- Control-IQ technology 2.0
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes Mellitus
One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™
The purpose of this trial is to evaluate the long-term safety in subjects previously implanted with VC-01™ combination product.
- Trial name
- NCT02939118
- Volunteers
- 51 people
- Sponsor
- ViaCyte
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII])…
- Trial name
- NCT01109316
- Testing
- Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as tablets in healthy volunteers and subjects with type…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01028404
- Testing
- NN1952, insulin aspart
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study
This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart NovoRapid® (U100/mL) in participants with…
- Trial name
- NCT05754424
- Testing
- AT278, NovoRapid, Humulin R 500 UNT/ML Injectable Solution
- Where
- Austria
- Volunteers
- 41 people
- Sponsor
- Arecor Limited
Diabetes Mellitus, Type 2
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
20 eligible subjects will be enrolled into the treatment phase of the trial.
- Trial name
- NCT00642538
- Testing
- MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers
The primary purpose of this study is to evaluate pharmacodynamics of single oral doses of PF-05175157 in a dose-dependent fashion in healthy volunteers
- Trial name
- NCT01537497
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes, Diabetic Cardiomyopathies
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT04826159
- Testing
- IMB-1018972
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin.
A non-interventional, multicentre study to observe the main criteria used in clinical practice by physicians when selecting the second-line add-on therapy in patients with inadequately metformin-controlled type 2 diabetes in 2…
- Trial name
- REALITY (NCT02355145)
- Where
- 3 sites in Bulgaria
- Volunteers
- 1,005 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus, T1D
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103.
- Conditions
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
- Trial name
- NCT06783309
- Testing
- CNP-103
- Where
- 45 sites in United States
- Volunteers
- 72 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.